nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—systemic lupus erythematosus	0.293	0.678	CbGaD
Pomalidomide—PTGS2—systemic lupus erythematosus	0.139	0.322	CbGaD
Pomalidomide—PTGS2—Dapsone—systemic lupus erythematosus	0.0509	0.139	CbGbCtD
Pomalidomide—PTGS2—Triamcinolone—systemic lupus erythematosus	0.0441	0.12	CbGbCtD
Pomalidomide—PTGS2—Betamethasone—systemic lupus erythematosus	0.0378	0.103	CbGbCtD
Pomalidomide—CYP1A2—Leflunomide—systemic lupus erythematosus	0.0269	0.0735	CbGbCtD
Pomalidomide—PTGS2—Dexamethasone—systemic lupus erythematosus	0.022	0.0601	CbGbCtD
Pomalidomide—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.0192	0.0524	CbGbCtD
Pomalidomide—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0145	0.0397	CbGbCtD
Pomalidomide—ABCB1—Betamethasone—systemic lupus erythematosus	0.0125	0.0341	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—systemic lupus erythematosus	0.0123	0.0336	CbGbCtD
Pomalidomide—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.0117	0.0319	CbGbCtD
Pomalidomide—ABCB1—Prednisone—systemic lupus erythematosus	0.0116	0.0317	CbGbCtD
Pomalidomide—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.0115	0.0314	CbGbCtD
Pomalidomide—ABCB1—Cyclosporine—systemic lupus erythematosus	0.011	0.0301	CbGbCtD
Pomalidomide—CYP3A4—Dapsone—systemic lupus erythematosus	0.0101	0.0274	CbGbCtD
Pomalidomide—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00872	0.0238	CbGbCtD
Pomalidomide—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00872	0.0238	CbGbCtD
Pomalidomide—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00748	0.0204	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00738	0.0201	CbGbCtD
Pomalidomide—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00726	0.0198	CbGbCtD
Pomalidomide—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00699	0.0191	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—systemic lupus erythematosus	0.00697	0.019	CbGbCtD
Pomalidomide—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00661	0.018	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—systemic lupus erythematosus	0.00583	0.0159	CbGbCtD
Pomalidomide—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00435	0.0119	CbGbCtD
Pomalidomide—CYP1A2—urine—systemic lupus erythematosus	0.00165	0.0876	CbGeAlD
Pomalidomide—CRBN—nephron tubule—systemic lupus erythematosus	0.00135	0.0718	CbGeAlD
Pomalidomide—CYP3A4—urine—systemic lupus erythematosus	0.00119	0.0634	CbGeAlD
Pomalidomide—Thalidomide—TNF—systemic lupus erythematosus	0.00119	0.441	CrCbGaD
Pomalidomide—CRBN—cortex of kidney—systemic lupus erythematosus	0.00116	0.0614	CbGeAlD
Pomalidomide—CRBN—lymphoid tissue—systemic lupus erythematosus	0.00102	0.0542	CbGeAlD
Pomalidomide—CRBN—tendon—systemic lupus erythematosus	0.000958	0.0509	CbGeAlD
Pomalidomide—Lenalidomide—PTGS2—systemic lupus erythematosus	0.000943	0.35	CrCbGaD
Pomalidomide—CRBN—bone marrow—systemic lupus erythematosus	0.000928	0.0493	CbGeAlD
Pomalidomide—CYP1A2—blood plasma—systemic lupus erythematosus	0.000861	0.0457	CbGeAlD
Pomalidomide—CRBN—lung—systemic lupus erythematosus	0.000841	0.0447	CbGeAlD
Pomalidomide—PTGS2—endothelium—systemic lupus erythematosus	0.000803	0.0427	CbGeAlD
Pomalidomide—CRBN—nervous system—systemic lupus erythematosus	0.000779	0.0414	CbGeAlD
Pomalidomide—CRBN—central nervous system—systemic lupus erythematosus	0.00075	0.0398	CbGeAlD
Pomalidomide—PTGS2—blood plasma—systemic lupus erythematosus	0.000713	0.0379	CbGeAlD
Pomalidomide—CYP3A4—blood plasma—systemic lupus erythematosus	0.000623	0.0331	CbGeAlD
Pomalidomide—Thalidomide—PTGS2—systemic lupus erythematosus	0.000565	0.209	CrCbGaD
Pomalidomide—ABCB1—blood plasma—systemic lupus erythematosus	0.000441	0.0234	CbGeAlD
Pomalidomide—PTGS2—Fluocinonide—Methylprednisolone—systemic lupus erythematosus	0.000411	0.159	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Dexamethasone—systemic lupus erythematosus	0.000404	0.156	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Betamethasone—systemic lupus erythematosus	0.000404	0.156	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Triamcinolone—systemic lupus erythematosus	0.000395	0.153	CbGdCrCtD
Pomalidomide—PTGS2—connective tissue—systemic lupus erythematosus	0.00038	0.0202	CbGeAlD
Pomalidomide—PTGS2—skin of body—systemic lupus erythematosus	0.000343	0.0182	CbGeAlD
Pomalidomide—PTGS2—kidney—systemic lupus erythematosus	0.000323	0.0172	CbGeAlD
Pomalidomide—CYP3A4—kidney—systemic lupus erythematosus	0.000282	0.015	CbGeAlD
Pomalidomide—PTGS2—lymphoid tissue—systemic lupus erythematosus	0.000278	0.0147	CbGeAlD
Pomalidomide—CYP1A2—lung—systemic lupus erythematosus	0.000276	0.0147	CbGeAlD
Pomalidomide—PTGS2—tendon—systemic lupus erythematosus	0.000261	0.0139	CbGeAlD
Pomalidomide—PTGS2—bone marrow—systemic lupus erythematosus	0.000253	0.0134	CbGeAlD
Pomalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—systemic lupus erythematosus	0.000248	0.0957	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Betamethasone—systemic lupus erythematosus	0.000244	0.0942	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—systemic lupus erythematosus	0.000244	0.0942	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—systemic lupus erythematosus	0.000238	0.0921	CbGdCrCtD
Pomalidomide—PTGS2—lung—systemic lupus erythematosus	0.000229	0.0122	CbGeAlD
Pomalidomide—ABCB1—nephron tubule—systemic lupus erythematosus	0.000227	0.0121	CbGeAlD
Pomalidomide—PTGS2—nervous system—systemic lupus erythematosus	0.000212	0.0113	CbGeAlD
Pomalidomide—PTGS2—central nervous system—systemic lupus erythematosus	0.000204	0.0108	CbGeAlD
Pomalidomide—ABCB1—kidney—systemic lupus erythematosus	0.0002	0.0106	CbGeAlD
Pomalidomide—ABCB1—cortex of kidney—systemic lupus erythematosus	0.000195	0.0103	CbGeAlD
Pomalidomide—CYP3A4—nervous system—systemic lupus erythematosus	0.000185	0.00985	CbGeAlD
Pomalidomide—CYP3A4—central nervous system—systemic lupus erythematosus	0.000178	0.00948	CbGeAlD
Pomalidomide—ABCB1—lymphoid tissue—systemic lupus erythematosus	0.000172	0.00912	CbGeAlD
Pomalidomide—ABCB1—bone marrow—systemic lupus erythematosus	0.000156	0.00831	CbGeAlD
Pomalidomide—ABCB1—lung—systemic lupus erythematosus	0.000142	0.00753	CbGeAlD
Pomalidomide—ABCB1—nervous system—systemic lupus erythematosus	0.000131	0.00697	CbGeAlD
Pomalidomide—ABCB1—central nervous system—systemic lupus erythematosus	0.000126	0.00671	CbGeAlD
Pomalidomide—Pruritus—Leflunomide—systemic lupus erythematosus	0.000118	0.00118	CcSEcCtD
Pomalidomide—Connective tissue disorder—Prednisone—systemic lupus erythematosus	0.000117	0.00118	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Cyclosporine—systemic lupus erythematosus	0.000117	0.00118	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—systemic lupus erythematosus	0.000116	0.00117	CcSEcCtD
Pomalidomide—Dizziness—Azathioprine—systemic lupus erythematosus	0.000116	0.00117	CcSEcCtD
Pomalidomide—Insomnia—Cyclosporine—systemic lupus erythematosus	0.000116	0.00117	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—systemic lupus erythematosus	0.000116	0.00117	CcSEcCtD
Pomalidomide—Cough—Triamcinolone—systemic lupus erythematosus	0.000115	0.00115	CcSEcCtD
Pomalidomide—Dyspnoea—Cyclosporine—systemic lupus erythematosus	0.000114	0.00115	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic lupus erythematosus	0.000114	0.00115	CcSEcCtD
Pomalidomide—Diarrhoea—Leflunomide—systemic lupus erythematosus	0.000114	0.00114	CcSEcCtD
Pomalidomide—Infection—Hydrocortisone—systemic lupus erythematosus	0.000113	0.00114	CcSEcCtD
Pomalidomide—Insomnia—Mycophenolate mofetil—systemic lupus erythematosus	0.000113	0.00114	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisolone—systemic lupus erythematosus	0.000113	0.00113	CcSEcCtD
Pomalidomide—Vomiting—Azathioprine—systemic lupus erythematosus	0.000112	0.00113	CcSEcCtD
Pomalidomide—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	0.000112	0.00112	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—systemic lupus erythematosus	0.000112	0.00112	CcSEcCtD
Pomalidomide—Arthralgia—Methylprednisolone—systemic lupus erythematosus	0.000112	0.00112	CcSEcCtD
Pomalidomide—Dyspnoea—Mycophenolate mofetil—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Decreased appetite—Cyclosporine—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Anxiety—Methylprednisolone—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Rash—Azathioprine—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Dermatitis—Azathioprine—systemic lupus erythematosus	0.000111	0.00112	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Pomalidomide—Skin disorder—Hydrocortisone—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Pomalidomide—Fatigue—Cyclosporine—systemic lupus erythematosus	0.000111	0.00111	CcSEcCtD
Pomalidomide—Headache—Azathioprine—systemic lupus erythematosus	0.00011	0.00111	CcSEcCtD
Pomalidomide—Hyperhidrosis—Hydrocortisone—systemic lupus erythematosus	0.00011	0.00111	CcSEcCtD
Pomalidomide—Dizziness—Leflunomide—systemic lupus erythematosus	0.00011	0.00111	CcSEcCtD
Pomalidomide—Pain—Cyclosporine—systemic lupus erythematosus	0.00011	0.0011	CcSEcCtD
Pomalidomide—Constipation—Cyclosporine—systemic lupus erythematosus	0.00011	0.0011	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—systemic lupus erythematosus	0.000109	0.0011	CcSEcCtD
Pomalidomide—Decreased appetite—Mycophenolate mofetil—systemic lupus erythematosus	0.000109	0.00109	CcSEcCtD
Pomalidomide—Angiopathy—Prednisone—systemic lupus erythematosus	0.000108	0.00109	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	0.000108	0.00109	CcSEcCtD
Pomalidomide—Confusional state—Methylprednisolone—systemic lupus erythematosus	0.000108	0.00109	CcSEcCtD
Pomalidomide—Vertigo—Betamethasone—systemic lupus erythematosus	0.000107	0.00108	CcSEcCtD
Pomalidomide—Vertigo—Dexamethasone—systemic lupus erythematosus	0.000107	0.00108	CcSEcCtD
Pomalidomide—Pain—Mycophenolate mofetil—systemic lupus erythematosus	0.000107	0.00108	CcSEcCtD
Pomalidomide—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	0.000107	0.00108	CcSEcCtD
Pomalidomide—Infection—Triamcinolone—systemic lupus erythematosus	0.000107	0.00107	CcSEcCtD
Pomalidomide—Infection—Methylprednisolone—systemic lupus erythematosus	0.000106	0.00107	CcSEcCtD
Pomalidomide—Feeling abnormal—Cyclosporine—systemic lupus erythematosus	0.000106	0.00106	CcSEcCtD
Pomalidomide—Vomiting—Leflunomide—systemic lupus erythematosus	0.000106	0.00106	CcSEcCtD
Pomalidomide—Insomnia—Prednisolone—systemic lupus erythematosus	0.000106	0.00106	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—systemic lupus erythematosus	0.000105	0.00106	CcSEcCtD
Pomalidomide—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	0.000105	0.00106	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—systemic lupus erythematosus	0.000105	0.00105	CcSEcCtD
Pomalidomide—Rash—Leflunomide—systemic lupus erythematosus	0.000105	0.00105	CcSEcCtD
Pomalidomide—Dermatitis—Leflunomide—systemic lupus erythematosus	0.000105	0.00105	CcSEcCtD
Pomalidomide—Mental disorder—Prednisone—systemic lupus erythematosus	0.000105	0.00105	CcSEcCtD
Pomalidomide—Nausea—Azathioprine—systemic lupus erythematosus	0.000104	0.00105	CcSEcCtD
Pomalidomide—Headache—Leflunomide—systemic lupus erythematosus	0.000104	0.00105	CcSEcCtD
Pomalidomide—Skin disorder—Methylprednisolone—systemic lupus erythematosus	0.000104	0.00105	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—systemic lupus erythematosus	0.000104	0.00105	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	0.000104	0.00104	CcSEcCtD
Pomalidomide—Hyperhidrosis—Triamcinolone—systemic lupus erythematosus	0.000104	0.00104	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methylprednisolone—systemic lupus erythematosus	0.000103	0.00104	CcSEcCtD
Pomalidomide—Feeling abnormal—Mycophenolate mofetil—systemic lupus erythematosus	0.000103	0.00104	CcSEcCtD
Pomalidomide—Insomnia—Hydrocortisone—systemic lupus erythematosus	0.000103	0.00104	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—systemic lupus erythematosus	0.000102	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—systemic lupus erythematosus	0.000102	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1A—systemic lupus erythematosus	0.000102	0.00131	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	0.000102	0.0013	CbGpPWpGaD
Pomalidomide—Body temperature increased—Cyclosporine—systemic lupus erythematosus	0.000101	0.00102	CcSEcCtD
Pomalidomide—Anxiety—Betamethasone—systemic lupus erythematosus	0.000101	0.00102	CcSEcCtD
Pomalidomide—Anxiety—Dexamethasone—systemic lupus erythematosus	0.000101	0.00102	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—RASGRP1—systemic lupus erythematosus	0.000101	0.0013	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CXCL12—systemic lupus erythematosus	0.0001	0.00129	CbGpPWpGaD
Pomalidomide—Pain—Prednisolone—systemic lupus erythematosus	9.98e-05	0.001	CcSEcCtD
Pomalidomide—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	9.9e-05	0.000997	CcSEcCtD
Pomalidomide—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	9.89e-05	0.000995	CcSEcCtD
Pomalidomide—Nausea—Leflunomide—systemic lupus erythematosus	9.87e-05	0.000993	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	9.85e-05	0.000991	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—systemic lupus erythematosus	9.84e-05	0.00126	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	9.84e-05	0.00099	CcSEcCtD
Pomalidomide—Fatigue—Hydrocortisone—systemic lupus erythematosus	9.82e-05	0.000989	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—systemic lupus erythematosus	9.77e-05	0.000984	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	9.77e-05	0.000984	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	9.75e-05	0.000981	CcSEcCtD
Pomalidomide—Pain—Hydrocortisone—systemic lupus erythematosus	9.74e-05	0.000981	CcSEcCtD
Pomalidomide—CYP1A2—Phase II conjugation—NAT2—systemic lupus erythematosus	9.74e-05	0.00125	CbGpPWpGaD
Pomalidomide—Insomnia—Triamcinolone—systemic lupus erythematosus	9.7e-05	0.000977	CcSEcCtD
Pomalidomide—Insomnia—Methylprednisolone—systemic lupus erythematosus	9.68e-05	0.000974	CcSEcCtD
Pomalidomide—Infection—Betamethasone—systemic lupus erythematosus	9.67e-05	0.000973	CcSEcCtD
Pomalidomide—Infection—Dexamethasone—systemic lupus erythematosus	9.67e-05	0.000973	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL17A—systemic lupus erythematosus	9.66e-05	0.00124	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisolone—systemic lupus erythematosus	9.61e-05	0.000967	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—systemic lupus erythematosus	9.6e-05	0.000966	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	9.57e-05	0.00123	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—systemic lupus erythematosus	9.57e-05	0.00123	CbGpPWpGaD
Pomalidomide—Dyspnoea—Triamcinolone—systemic lupus erythematosus	9.56e-05	0.000963	CcSEcCtD
Pomalidomide—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	9.55e-05	0.000961	CcSEcCtD
Pomalidomide—Nervous system disorder—Betamethasone—systemic lupus erythematosus	9.55e-05	0.000961	CcSEcCtD
Pomalidomide—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	9.53e-05	0.000959	CcSEcCtD
Pomalidomide—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	9.53e-05	0.000959	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—EP300—systemic lupus erythematosus	9.52e-05	0.00122	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	9.5e-05	0.00122	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—systemic lupus erythematosus	9.48e-05	0.00122	CbGpPWpGaD
Pomalidomide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	9.46e-05	0.00122	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	9.44e-05	0.000951	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	9.41e-05	0.00121	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	9.41e-05	0.000947	CcSEcCtD
Pomalidomide—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	9.41e-05	0.000947	CcSEcCtD
Pomalidomide—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	9.39e-05	0.000945	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—systemic lupus erythematosus	9.33e-05	0.000939	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—NR3C1—systemic lupus erythematosus	9.3e-05	0.0012	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Methotrexate—systemic lupus erythematosus	9.25e-05	0.000931	CcSEcCtD
Pomalidomide—Fatigue—Triamcinolone—systemic lupus erythematosus	9.25e-05	0.000931	CcSEcCtD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	9.24e-05	0.00119	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—GADD45A—systemic lupus erythematosus	9.23e-05	0.00119	CbGpPWpGaD
Pomalidomide—Fatigue—Methylprednisolone—systemic lupus erythematosus	9.23e-05	0.000929	CcSEcCtD
Pomalidomide—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	9.21e-05	0.000927	CcSEcCtD
Pomalidomide—Asthenia—Cyclosporine—systemic lupus erythematosus	9.2e-05	0.000926	CcSEcCtD
Pomalidomide—Pain—Triamcinolone—systemic lupus erythematosus	9.17e-05	0.000923	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CCL2—systemic lupus erythematosus	9.17e-05	0.00118	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CD80—systemic lupus erythematosus	9.08e-05	0.00117	CbGpPWpGaD
Pomalidomide—Pruritus—Cyclosporine—systemic lupus erythematosus	9.07e-05	0.000913	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—systemic lupus erythematosus	9.05e-05	0.000911	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—systemic lupus erythematosus	9.04e-05	0.00116	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—systemic lupus erythematosus	9.04e-05	0.00116	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—FAS—systemic lupus erythematosus	9.01e-05	0.00116	CbGpPWpGaD
Pomalidomide—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	9.01e-05	0.000906	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	8.99e-05	0.000904	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL12B—systemic lupus erythematosus	8.98e-05	0.00115	CbGpPWpGaD
Pomalidomide—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	8.97e-05	0.000903	CcSEcCtD
Pomalidomide—Chills—Methotrexate—systemic lupus erythematosus	8.95e-05	0.0009	CcSEcCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—systemic lupus erythematosus	8.9e-05	0.00114	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	8.87e-05	0.000893	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	8.87e-05	0.000893	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—ALB—systemic lupus erythematosus	8.85e-05	0.00114	CbGpPWpGaD
Pomalidomide—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	8.85e-05	0.00089	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—systemic lupus erythematosus	8.84e-05	0.00089	CcSEcCtD
Pomalidomide—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	8.84e-05	0.00089	CcSEcCtD
Pomalidomide—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	8.82e-05	0.000888	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—systemic lupus erythematosus	8.81e-05	0.000887	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IFNG—systemic lupus erythematosus	8.81e-05	0.00113	CbGpPWpGaD
Pomalidomide—Insomnia—Betamethasone—systemic lupus erythematosus	8.8e-05	0.000886	CcSEcCtD
Pomalidomide—Insomnia—Dexamethasone—systemic lupus erythematosus	8.8e-05	0.000886	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	8.78e-05	0.000884	CcSEcCtD
Pomalidomide—Diarrhoea—Cyclosporine—systemic lupus erythematosus	8.77e-05	0.000883	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TLR4—systemic lupus erythematosus	8.76e-05	0.00113	CbGpPWpGaD
Pomalidomide—Mental disorder—Methotrexate—systemic lupus erythematosus	8.74e-05	0.000879	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—systemic lupus erythematosus	8.69e-05	0.00112	CbGpPWpGaD
Pomalidomide—Malnutrition—Methotrexate—systemic lupus erythematosus	8.68e-05	0.000874	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CXCL12—systemic lupus erythematosus	8.67e-05	0.00111	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisolone—systemic lupus erythematosus	8.59e-05	0.000865	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CD40—systemic lupus erythematosus	8.57e-05	0.0011	CbGpPWpGaD
Pomalidomide—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	8.56e-05	0.000861	CcSEcCtD
Pomalidomide—Body temperature increased—Triamcinolone—systemic lupus erythematosus	8.48e-05	0.000853	CcSEcCtD
Pomalidomide—Dizziness—Cyclosporine—systemic lupus erythematosus	8.48e-05	0.000853	CcSEcCtD
Pomalidomide—Decreased appetite—Betamethasone—systemic lupus erythematosus	8.46e-05	0.000852	CcSEcCtD
Pomalidomide—Decreased appetite—Dexamethasone—systemic lupus erythematosus	8.46e-05	0.000852	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—CTLA4—systemic lupus erythematosus	8.44e-05	0.00109	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—systemic lupus erythematosus	8.44e-05	0.00108	CbGpPWpGaD
Pomalidomide—Infection—Prednisone—systemic lupus erythematosus	8.42e-05	0.000848	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	8.4e-05	0.000846	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	8.4e-05	0.000846	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—systemic lupus erythematosus	8.4e-05	0.000845	CcSEcCtD
Pomalidomide—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	8.39e-05	0.000845	CcSEcCtD
Pomalidomide—Fatigue—Dexamethasone—systemic lupus erythematosus	8.39e-05	0.000845	CcSEcCtD
Pomalidomide—Fatigue—Betamethasone—systemic lupus erythematosus	8.39e-05	0.000845	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	8.39e-05	0.00108	CbGpPWpGaD
Pomalidomide—Pain—Dexamethasone—systemic lupus erythematosus	8.32e-05	0.000838	CcSEcCtD
Pomalidomide—Pain—Betamethasone—systemic lupus erythematosus	8.32e-05	0.000838	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—systemic lupus erythematosus	8.31e-05	0.000837	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—systemic lupus erythematosus	8.28e-05	0.00106	CbGpPWpGaD
Pomalidomide—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	8.27e-05	0.000832	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—systemic lupus erythematosus	8.23e-05	0.000829	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—systemic lupus erythematosus	8.19e-05	0.000825	CcSEcCtD
Pomalidomide—Asthenia—Hydrocortisone—systemic lupus erythematosus	8.17e-05	0.000823	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	8.16e-05	0.00105	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—systemic lupus erythematosus	8.16e-05	0.00105	CbGpPWpGaD
Pomalidomide—Vomiting—Cyclosporine—systemic lupus erythematosus	8.15e-05	0.00082	CcSEcCtD
Pomalidomide—TNF—Apoptosis—FASLG—systemic lupus erythematosus	8.12e-05	0.00104	CbGpPWpGaD
Pomalidomide—Rash—Cyclosporine—systemic lupus erythematosus	8.08e-05	0.000813	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	8.08e-05	0.00104	CbGpPWpGaD
Pomalidomide—Dermatitis—Cyclosporine—systemic lupus erythematosus	8.08e-05	0.000813	CcSEcCtD
Pomalidomide—Pruritus—Hydrocortisone—systemic lupus erythematosus	8.06e-05	0.000811	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NR3C1—systemic lupus erythematosus	8.04e-05	0.00103	CbGpPWpGaD
Pomalidomide—Headache—Cyclosporine—systemic lupus erythematosus	8.03e-05	0.000808	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—systemic lupus erythematosus	8.02e-05	0.000807	CcSEcCtD
Pomalidomide—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	8.02e-05	0.000807	CcSEcCtD
Pomalidomide—Feeling abnormal—Betamethasone—systemic lupus erythematosus	8.02e-05	0.000807	CcSEcCtD
Pomalidomide—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	7.95e-05	0.0008	CcSEcCtD
Pomalidomide—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	7.9e-05	0.000795	CcSEcCtD
Pomalidomide—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	7.89e-05	0.000794	CcSEcCtD
Pomalidomide—Rash—Mycophenolate mofetil—systemic lupus erythematosus	7.88e-05	0.000794	CcSEcCtD
Pomalidomide—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	7.88e-05	0.000793	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—systemic lupus erythematosus	7.85e-05	0.00101	CbGpPWpGaD
Pomalidomide—Headache—Mycophenolate mofetil—systemic lupus erythematosus	7.83e-05	0.000788	CcSEcCtD
Pomalidomide—TNF—Apoptosis—FAS—systemic lupus erythematosus	7.83e-05	0.00101	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—systemic lupus erythematosus	7.83e-05	0.00101	CbGpPWpGaD
Pomalidomide—Vertigo—Methotrexate—systemic lupus erythematosus	7.8e-05	0.000785	CcSEcCtD
Pomalidomide—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	7.79e-05	0.000785	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—systemic lupus erythematosus	7.77e-05	0.000782	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—systemic lupus erythematosus	7.75e-05	0.000995	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—EP300—systemic lupus erythematosus	7.74e-05	0.000994	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	7.72e-05	0.000777	CcSEcCtD
Pomalidomide—Dizziness—Prednisolone—systemic lupus erythematosus	7.71e-05	0.000776	CcSEcCtD
Pomalidomide—Asthenia—Triamcinolone—systemic lupus erythematosus	7.7e-05	0.000775	CcSEcCtD
Pomalidomide—Body temperature increased—Dexamethasone—systemic lupus erythematosus	7.69e-05	0.000774	CcSEcCtD
Pomalidomide—Body temperature increased—Betamethasone—systemic lupus erythematosus	7.69e-05	0.000774	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—systemic lupus erythematosus	7.68e-05	0.000987	CbGpPWpGaD
Pomalidomide—Asthenia—Methylprednisolone—systemic lupus erythematosus	7.68e-05	0.000773	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—systemic lupus erythematosus	7.67e-05	0.000772	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—systemic lupus erythematosus	7.63e-05	0.00098	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	7.62e-05	0.00098	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FASLG—systemic lupus erythematosus	7.61e-05	0.000979	CbGpPWpGaD
Pomalidomide—Nausea—Cyclosporine—systemic lupus erythematosus	7.61e-05	0.000766	CcSEcCtD
Pomalidomide—Pruritus—Triamcinolone—systemic lupus erythematosus	7.59e-05	0.000764	CcSEcCtD
Pomalidomide—Cough—Methotrexate—systemic lupus erythematosus	7.57e-05	0.000762	CcSEcCtD
Pomalidomide—Pruritus—Methylprednisolone—systemic lupus erythematosus	7.57e-05	0.000762	CcSEcCtD
Pomalidomide—Dizziness—Hydrocortisone—systemic lupus erythematosus	7.53e-05	0.000758	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CCL2—systemic lupus erythematosus	7.51e-05	0.000966	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQA1—systemic lupus erythematosus	7.43e-05	0.000955	CbGpPWpGaD
Pomalidomide—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	7.43e-05	0.000748	CcSEcCtD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	7.42e-05	0.000953	CbGpPWpGaD
Pomalidomide—Arthralgia—Methotrexate—systemic lupus erythematosus	7.39e-05	0.000744	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	7.37e-05	0.000948	CbGpPWpGaD
Pomalidomide—Decreased appetite—Prednisone—systemic lupus erythematosus	7.37e-05	0.000742	CcSEcCtD
Pomalidomide—Rash—Prednisolone—systemic lupus erythematosus	7.35e-05	0.00074	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—systemic lupus erythematosus	7.35e-05	0.00074	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—FAS—systemic lupus erythematosus	7.34e-05	0.000944	CbGpPWpGaD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	7.34e-05	0.000739	CcSEcCtD
Pomalidomide—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	7.32e-05	0.000737	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—systemic lupus erythematosus	7.31e-05	0.000736	CcSEcCtD
Pomalidomide—Headache—Prednisolone—systemic lupus erythematosus	7.31e-05	0.000735	CcSEcCtD
Pomalidomide—Constipation—Prednisone—systemic lupus erythematosus	7.25e-05	0.00073	CcSEcCtD
Pomalidomide—Vomiting—Hydrocortisone—systemic lupus erythematosus	7.24e-05	0.000729	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—PPARG—systemic lupus erythematosus	7.21e-05	0.000926	CbGpPWpGaD
Pomalidomide—Rash—Hydrocortisone—systemic lupus erythematosus	7.18e-05	0.000723	CcSEcCtD
Pomalidomide—Dermatitis—Hydrocortisone—systemic lupus erythematosus	7.18e-05	0.000722	CcSEcCtD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—systemic lupus erythematosus	7.17e-05	0.000921	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CRP—systemic lupus erythematosus	7.14e-05	0.000918	CbGpPWpGaD
Pomalidomide—Confusional state—Methotrexate—systemic lupus erythematosus	7.14e-05	0.000719	CcSEcCtD
Pomalidomide—Headache—Hydrocortisone—systemic lupus erythematosus	7.14e-05	0.000718	CcSEcCtD
Pomalidomide—Dizziness—Triamcinolone—systemic lupus erythematosus	7.09e-05	0.000714	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CD80—systemic lupus erythematosus	7.09e-05	0.000911	CbGpPWpGaD
Pomalidomide—Dizziness—Methylprednisolone—systemic lupus erythematosus	7.08e-05	0.000712	CcSEcCtD
Pomalidomide—Infection—Methotrexate—systemic lupus erythematosus	7.04e-05	0.000708	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	7.04e-05	0.000904	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisone—systemic lupus erythematosus	6.99e-05	0.000703	CcSEcCtD
Pomalidomide—Asthenia—Betamethasone—systemic lupus erythematosus	6.98e-05	0.000703	CcSEcCtD
Pomalidomide—Asthenia—Dexamethasone—systemic lupus erythematosus	6.98e-05	0.000703	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—systemic lupus erythematosus	6.98e-05	0.000897	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQB1—systemic lupus erythematosus	6.95e-05	0.000894	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Methotrexate—systemic lupus erythematosus	6.95e-05	0.000699	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	6.94e-05	0.000698	CcSEcCtD
Pomalidomide—Nausea—Prednisolone—systemic lupus erythematosus	6.93e-05	0.000697	CcSEcCtD
Pomalidomide—Pruritus—Betamethasone—systemic lupus erythematosus	6.89e-05	0.000693	CcSEcCtD
Pomalidomide—Pruritus—Dexamethasone—systemic lupus erythematosus	6.89e-05	0.000693	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—systemic lupus erythematosus	6.88e-05	0.000693	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	6.87e-05	0.000883	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	6.85e-05	0.000689	CcSEcCtD
Pomalidomide—Vomiting—Triamcinolone—systemic lupus erythematosus	6.82e-05	0.000686	CcSEcCtD
Pomalidomide—Vomiting—Methylprednisolone—systemic lupus erythematosus	6.81e-05	0.000685	CcSEcCtD
Pomalidomide—Nausea—Hydrocortisone—systemic lupus erythematosus	6.77e-05	0.000681	CcSEcCtD
Pomalidomide—Rash—Triamcinolone—systemic lupus erythematosus	6.76e-05	0.000681	CcSEcCtD
Pomalidomide—Dermatitis—Triamcinolone—systemic lupus erythematosus	6.76e-05	0.00068	CcSEcCtD
Pomalidomide—Rash—Methylprednisolone—systemic lupus erythematosus	6.75e-05	0.000679	CcSEcCtD
Pomalidomide—Dermatitis—Methylprednisolone—systemic lupus erythematosus	6.74e-05	0.000679	CcSEcCtD
Pomalidomide—Headache—Triamcinolone—systemic lupus erythematosus	6.72e-05	0.000676	CcSEcCtD
Pomalidomide—Headache—Methylprednisolone—systemic lupus erythematosus	6.71e-05	0.000675	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—systemic lupus erythematosus	6.7e-05	0.000674	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	6.69e-05	0.00086	CbGpPWpGaD
Pomalidomide—Diarrhoea—Dexamethasone—systemic lupus erythematosus	6.66e-05	0.00067	CcSEcCtD
Pomalidomide—Diarrhoea—Betamethasone—systemic lupus erythematosus	6.66e-05	0.00067	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—VEGFA—systemic lupus erythematosus	6.65e-05	0.000855	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	6.63e-05	0.000852	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—F2—systemic lupus erythematosus	6.59e-05	0.000847	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—systemic lupus erythematosus	6.57e-05	0.000844	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD40LG—systemic lupus erythematosus	6.57e-05	0.000844	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL4—systemic lupus erythematosus	6.54e-05	0.00084	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—systemic lupus erythematosus	6.53e-05	0.000839	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	6.45e-05	0.00065	CcSEcCtD
Pomalidomide—Dizziness—Dexamethasone—systemic lupus erythematosus	6.44e-05	0.000648	CcSEcCtD
Pomalidomide—Dizziness—Betamethasone—systemic lupus erythematosus	6.44e-05	0.000648	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—systemic lupus erythematosus	6.41e-05	0.000645	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—systemic lupus erythematosus	6.39e-05	0.000821	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL4—systemic lupus erythematosus	6.39e-05	0.000821	CbGpPWpGaD
Pomalidomide—Nausea—Triamcinolone—systemic lupus erythematosus	6.37e-05	0.000641	CcSEcCtD
Pomalidomide—Nausea—Methylprednisolone—systemic lupus erythematosus	6.36e-05	0.00064	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	6.34e-05	0.000815	CbGpPWpGaD
Pomalidomide—Dyspnoea—Methotrexate—systemic lupus erythematosus	6.32e-05	0.000636	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	6.28e-05	0.000807	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisone—systemic lupus erythematosus	6.25e-05	0.000629	CcSEcCtD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic lupus erythematosus	6.23e-05	0.000801	CbGpPWpGaD
Pomalidomide—Vomiting—Betamethasone—systemic lupus erythematosus	6.19e-05	0.000623	CcSEcCtD
Pomalidomide—Vomiting—Dexamethasone—systemic lupus erythematosus	6.19e-05	0.000623	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—systemic lupus erythematosus	6.16e-05	0.00062	CcSEcCtD
Pomalidomide—Rash—Dexamethasone—systemic lupus erythematosus	6.14e-05	0.000618	CcSEcCtD
Pomalidomide—Rash—Betamethasone—systemic lupus erythematosus	6.14e-05	0.000618	CcSEcCtD
Pomalidomide—Dermatitis—Dexamethasone—systemic lupus erythematosus	6.13e-05	0.000617	CcSEcCtD
Pomalidomide—Dermatitis—Betamethasone—systemic lupus erythematosus	6.13e-05	0.000617	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—systemic lupus erythematosus	6.13e-05	0.000787	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	6.12e-05	0.000616	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—systemic lupus erythematosus	6.11e-05	0.000615	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—TGFB1—systemic lupus erythematosus	6.11e-05	0.000785	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FASLG—systemic lupus erythematosus	6.11e-05	0.000785	CbGpPWpGaD
Pomalidomide—Headache—Betamethasone—systemic lupus erythematosus	6.1e-05	0.000614	CcSEcCtD
Pomalidomide—Headache—Dexamethasone—systemic lupus erythematosus	6.1e-05	0.000614	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—systemic lupus erythematosus	6.08e-05	0.000612	CcSEcCtD
Pomalidomide—Pain—Methotrexate—systemic lupus erythematosus	6.06e-05	0.00061	CcSEcCtD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	6.01e-05	0.000772	CbGpPWpGaD
Pomalidomide—Pruritus—Prednisone—systemic lupus erythematosus	6e-05	0.000604	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	5.92e-05	0.000761	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FAS—systemic lupus erythematosus	5.89e-05	0.000756	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	5.88e-05	0.000755	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2RA—systemic lupus erythematosus	5.85e-05	0.000752	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methotrexate—systemic lupus erythematosus	5.84e-05	0.000588	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic lupus erythematosus	5.81e-05	0.000747	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—C3—systemic lupus erythematosus	5.8e-05	0.000746	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDKN1B—systemic lupus erythematosus	5.8e-05	0.000746	CbGpPWpGaD
Pomalidomide—Diarrhoea—Prednisone—systemic lupus erythematosus	5.8e-05	0.000584	CcSEcCtD
Pomalidomide—Nausea—Betamethasone—systemic lupus erythematosus	5.78e-05	0.000582	CcSEcCtD
Pomalidomide—Nausea—Dexamethasone—systemic lupus erythematosus	5.78e-05	0.000582	CcSEcCtD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	5.74e-05	0.000737	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	5.72e-05	0.000735	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—NAT2—systemic lupus erythematosus	5.7e-05	0.000732	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	5.69e-05	0.000731	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—systemic lupus erythematosus	5.68e-05	0.00073	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—LYN—systemic lupus erythematosus	5.67e-05	0.000728	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—NAT2—systemic lupus erythematosus	5.62e-05	0.000722	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—systemic lupus erythematosus	5.61e-05	0.000564	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—systemic lupus erythematosus	5.6e-05	0.000564	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ALB—systemic lupus erythematosus	5.48e-05	0.000704	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	5.43e-05	0.000698	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TLR4—systemic lupus erythematosus	5.42e-05	0.000696	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—systemic lupus erythematosus	5.39e-05	0.000542	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—systemic lupus erythematosus	5.37e-05	0.000691	CbGpPWpGaD
Pomalidomide—Rash—Prednisone—systemic lupus erythematosus	5.34e-05	0.000538	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—systemic lupus erythematosus	5.34e-05	0.000537	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL6—systemic lupus erythematosus	5.31e-05	0.000683	CbGpPWpGaD
Pomalidomide—Headache—Prednisone—systemic lupus erythematosus	5.31e-05	0.000534	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DRB1—systemic lupus erythematosus	5.29e-05	0.000679	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Methotrexate—systemic lupus erythematosus	5.22e-05	0.000525	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	5.19e-05	0.000667	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—systemic lupus erythematosus	5.14e-05	0.00066	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—systemic lupus erythematosus	5.08e-05	0.000653	CbGpPWpGaD
Pomalidomide—Asthenia—Methotrexate—systemic lupus erythematosus	5.08e-05	0.000512	CcSEcCtD
Pomalidomide—Nausea—Prednisone—systemic lupus erythematosus	5.03e-05	0.000507	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—systemic lupus erythematosus	5.01e-05	0.000504	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—systemic lupus erythematosus	5.01e-05	0.000644	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	5e-05	0.000642	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CDKN1A—systemic lupus erythematosus	4.96e-05	0.000637	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CD80—systemic lupus erythematosus	4.89e-05	0.000628	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PTPRC—systemic lupus erythematosus	4.85e-05	0.000623	CbGpPWpGaD
Pomalidomide—Diarrhoea—Methotrexate—systemic lupus erythematosus	4.85e-05	0.000488	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	4.75e-05	0.000611	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—systemic lupus erythematosus	4.71e-05	0.000605	CbGpPWpGaD
Pomalidomide—Dizziness—Methotrexate—systemic lupus erythematosus	4.68e-05	0.000471	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CCL2—systemic lupus erythematosus	4.65e-05	0.000597	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	4.64e-05	0.000596	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ADIPOQ—systemic lupus erythematosus	4.58e-05	0.000588	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—systemic lupus erythematosus	4.56e-05	0.000585	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—systemic lupus erythematosus	4.5e-05	0.000453	CcSEcCtD
Pomalidomide—Rash—Methotrexate—systemic lupus erythematosus	4.47e-05	0.00045	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—systemic lupus erythematosus	4.46e-05	0.000449	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	4.45e-05	0.000572	CbGpPWpGaD
Pomalidomide—Headache—Methotrexate—systemic lupus erythematosus	4.44e-05	0.000447	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—systemic lupus erythematosus	4.43e-05	0.000569	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	4.4e-05	0.000565	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—systemic lupus erythematosus	4.35e-05	0.000558	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	4.34e-05	0.000557	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	4.31e-05	0.000554	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	4.31e-05	0.000554	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	4.26e-05	0.000548	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	4.25e-05	0.000546	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	4.22e-05	0.000543	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	4.22e-05	0.000542	CbGpPWpGaD
Pomalidomide—Nausea—Methotrexate—systemic lupus erythematosus	4.21e-05	0.000424	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	4.2e-05	0.000539	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	4.17e-05	0.000535	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—EP300—systemic lupus erythematosus	4.14e-05	0.000531	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—TGFB1—systemic lupus erythematosus	4.1e-05	0.000527	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	4.1e-05	0.000527	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—EP300—systemic lupus erythematosus	4.08e-05	0.000524	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—systemic lupus erythematosus	4.07e-05	0.000523	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	3.98e-05	0.000512	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—systemic lupus erythematosus	3.95e-05	0.000508	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	3.95e-05	0.000507	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RXRA—systemic lupus erythematosus	3.92e-05	0.000504	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—systemic lupus erythematosus	3.86e-05	0.000496	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—systemic lupus erythematosus	3.86e-05	0.000496	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	3.79e-05	0.000487	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	3.79e-05	0.000487	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—systemic lupus erythematosus	3.75e-05	0.000482	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	3.68e-05	0.000473	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	3.64e-05	0.000468	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDKN1B—systemic lupus erythematosus	3.59e-05	0.000461	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	3.59e-05	0.000461	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	3.56e-05	0.000457	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—systemic lupus erythematosus	3.51e-05	0.000451	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	3.47e-05	0.000445	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—systemic lupus erythematosus	3.43e-05	0.000441	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	3.37e-05	0.000433	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—systemic lupus erythematosus	3.34e-05	0.000429	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—systemic lupus erythematosus	3.34e-05	0.000429	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—systemic lupus erythematosus	3.32e-05	0.000427	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—JAK1—systemic lupus erythematosus	3.3e-05	0.000424	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	3.29e-05	0.000423	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	3.28e-05	0.000422	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—systemic lupus erythematosus	3.23e-05	0.000416	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—RXRA—systemic lupus erythematosus	3.19e-05	0.00041	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—systemic lupus erythematosus	3.09e-05	0.000397	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	3.08e-05	0.000395	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	3.08e-05	0.000395	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	3.01e-05	0.000387	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	3.01e-05	0.000387	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—systemic lupus erythematosus	2.93e-05	0.000376	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—systemic lupus erythematosus	2.92e-05	0.000375	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	2.91e-05	0.000373	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—systemic lupus erythematosus	2.74e-05	0.000352	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—systemic lupus erythematosus	2.68e-05	0.000344	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—systemic lupus erythematosus	2.67e-05	0.000343	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	2.61e-05	0.000335	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—systemic lupus erythematosus	2.56e-05	0.000329	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—XRCC6—systemic lupus erythematosus	2.55e-05	0.000328	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—systemic lupus erythematosus	2.5e-05	0.000321	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARG—systemic lupus erythematosus	2.48e-05	0.000318	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	2.46e-05	0.000317	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	2.44e-05	0.000314	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	2.25e-05	0.000289	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TYK2—systemic lupus erythematosus	2.17e-05	0.000279	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.17e-05	0.000278	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	2.14e-05	0.000275	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—systemic lupus erythematosus	2.06e-05	0.000265	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	2.03e-05	0.000261	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HIST2H2AC—systemic lupus erythematosus	1.88e-05	0.000242	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	1.86e-05	0.000239	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CSK—systemic lupus erythematosus	1.83e-05	0.000235	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	1.83e-05	0.000235	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	1.74e-05	0.000224	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	1.73e-05	0.000222	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD247—systemic lupus erythematosus	1.72e-05	0.000221	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAT2—systemic lupus erythematosus	1.72e-05	0.000221	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—systemic lupus erythematosus	1.71e-05	0.00022	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NCF2—systemic lupus erythematosus	1.68e-05	0.000215	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EP300—systemic lupus erythematosus	1.62e-05	0.000208	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	1.6e-05	0.000205	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—systemic lupus erythematosus	1.53e-05	0.000197	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	1.52e-05	0.000195	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.46e-05	0.000188	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	1.44e-05	0.000185	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—systemic lupus erythematosus	1.41e-05	0.000181	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.37e-05	0.000176	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	1.32e-05	0.00017	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JUNB—systemic lupus erythematosus	1.31e-05	0.000169	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	1.23e-05	0.000158	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.23e-05	0.000158	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.23e-05	0.000158	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAT2—systemic lupus erythematosus	1.22e-05	0.000157	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRL—systemic lupus erythematosus	1.21e-05	0.000156	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—systemic lupus erythematosus	1.06e-05	0.000136	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAT2—systemic lupus erythematosus	9.74e-06	0.000125	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JAK1—systemic lupus erythematosus	9.69e-06	0.000124	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RXRA—systemic lupus erythematosus	9.65e-06	0.000124	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CCR5—systemic lupus erythematosus	9.18e-06	0.000118	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	8.95e-06	0.000115	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	8.29e-06	0.000107	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	7.74e-06	9.95e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD80—systemic lupus erythematosus	7.55e-06	9.7e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	7.52e-06	9.66e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	6.96e-06	8.95e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	6.84e-06	8.79e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TYK2—systemic lupus erythematosus	6.37e-06	8.19e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—systemic lupus erythematosus	6.26e-06	8.04e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—systemic lupus erythematosus	6.09e-06	7.83e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	6.09e-06	7.83e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—systemic lupus erythematosus	5.77e-06	7.41e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—systemic lupus erythematosus	5.48e-06	7.04e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	5.46e-06	7.02e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—systemic lupus erythematosus	5.42e-06	6.97e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—systemic lupus erythematosus	5.24e-06	6.73e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	5.07e-06	6.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—systemic lupus erythematosus	5e-06	6.43e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—systemic lupus erythematosus	4.76e-06	6.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	4.32e-06	5.55e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	4.21e-06	5.42e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—systemic lupus erythematosus	4.14e-06	5.32e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—systemic lupus erythematosus	3.99e-06	5.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—systemic lupus erythematosus	3.88e-06	4.99e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	3.71e-06	4.77e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	3.45e-06	4.43e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	3.4e-06	4.37e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—systemic lupus erythematosus	3.12e-06	4.01e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	3.1e-06	3.98e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	2.97e-06	3.81e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—systemic lupus erythematosus	2.83e-06	3.63e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	2.71e-06	3.49e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	2.66e-06	3.42e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	2.39e-06	3.07e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	2.29e-06	2.94e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	2.26e-06	2.9e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	2.09e-06	2.69e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	1.74e-06	2.24e-05	CbGpPWpGaD
